



## Financial Tear Sheet

### Corporate Profile

Otonomy is a biopharmaceutical company dedicated to the development of innovative therapeutics for diseases and disorders of the ear. The company pioneered the application of drug delivery technology to the ear in order to develop products that achieve sustained drug exposure from a single local administration. This approach is covered by a broad patent estate and is being utilized to develop a pipeline of products addressing important unmet medical needs including Ménière's disease, hearing loss, and tinnitus.

### Stock Performance

#### OTIC (Common Stock)

Exchange NASDAQ GS (US Dollar)

Price **\$5.68**


Change (%) ▼ **0.03 (0.35%)**

Volume 202,842

52 Week High \$21.15

52 Week Low \$2.80

Data as of 01/19/18 4:00 p.m. ET



Data Provided by Thomson Reuters

### Recent Headlines & Events

- 01/09/18 - 7:31 a.m.  
[Otonomy Provides Corporate and Product Pipeline Update](#)
- 01/04/18 - 7:31 a.m.  
[Otonomy to Present at the J.P. Morgan Healthcare Conference](#)

There are currently no events scheduled.

### SEC Filings

Filing Date	Form
01/09/18	8-K
12/22/17	8-K

### Primary IR Contact

E-mail: [ir@otonomy.com](mailto:ir@otonomy.com)